The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401
Bjornsson, T. D., Callaghan, J. T., Einolf, H. J., Fischer, V., Gan, L., Grimm, S., Kao, J., King, S. P., Miwa, G., Ni, L., et al. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.7.815 · Cited by 792
Self-citationVALIDATED ASSAYS FOR HUMAN CYTOCHROME P450 ACTIVITIES
Walsky, R. L., & Obach, R. S. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.6.647 · Cited by 507
Self-citationGorski, J. C., Jones, D. R., Haehner-Daniels, B. D., Hamman, M. A., O'Mara, E. M., & Hall, S. D. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90146-1 · Cited by 411
Scordo, M. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.129321 · Cited by 344
CYP3A4 drug interactions: correlation of 10 in vitro probe substrates
Kenworthy, Bloomer, Clarke, & Houston (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00073.x · Cited by 336
Jeppesen, U., Gram, L. F., Vistisen, K., Loft, S., Poulsen, H. E., & Brøsen, K. (1996) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050163 · Cited by 321
Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction
Thummel, K. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00039-2 · Cited by 318
Mayhew, B. S., Jones, D. R., & Hall, S. D. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15182-3 · Cited by 293
Tucker, G. T., Houston, J. B., & Huang, S. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.temp.1441.x · Cited by 284
Self-citation
Cited by
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Self-citationPhysiologically-Based Pharmacokinetics in Drug Development and Regulatory Science
Rowland, M., Peck, C., & Tucker, G. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100540 · Cited by 662
Inhibition and induction of human cytochrome P450 enzymes: current status
Pelkonen, O., Turpeinen, M., Hakkola, J., Honkakoski, P., Hukkanen, J., & Raunio, H. (2008) · Archives of Toxicology · doi:10.1007/s00204-008-0332-8 · Cited by 569
Obach, R. S., Walsky, R. L., & Venkatakrishnan, K. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.012633 · Cited by 460
Self-citationRational Approaches to Improving Selectivity in Drug Design
Huggins, D. J., Sherman, W., & Tidor, B. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm2010332 · Cited by 367
Development of new antiepileptic drugs: challenges, incentives, and recent advances
Perucca, E., French, J., & Bialer, M. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70215-6 · Cited by 339
Grimm, S. W., Einolf, H. J., Hall, S. D., He, K., Lim, H.-K., Ling, K.-H. J., Lu, C., Nomeir, A. A., Seibert, E., Skordos, K. W., et al. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.026716 · Cited by 310
Self-citationPredicting Drug–Drug Interactions: An FDA Perspective
Zhang, L., Zhang, Y., Zhao, P., & Huang, S.-M. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9106-3 · Cited by 267
Wang, L., Zhang, D., Raghavan, N., Yao, M., Ma, L., Frost, C. A., Maxwell, B. D., Chen, S.-Y., He, K., Goosen, T. C., et al. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.029694 · Cited by 253
Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability
Howgate, E. M., Rowland Yeo, K., Proctor, N. J., Tucker, G. T., & Rostami-Hodjegan, A. (2006) · Xenobiotica · doi:10.1080/00498250600683197 · Cited by 223
“This is also important for the prediction of metabolic drug–drug interactions since the outcome of such extrapolation is very sensitive to the correct assignment of the fraction of the dose of the target drug metabolized by the inhibited enzyme (fm(CYP)) (Rostami-Hodjegan and Tucker 2004; Brown et al. 2005; Ito et al.…”
BackgroundWarrilow, A. G. S., Hull, C. M., Parker, J. E., Garvey, E. P., Hoekstra, W. J., Moore, W. R., Schotzinger, R. J., Kelly, D. E., & Kelly, S. L. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03707-14 · Cited by 173
Barton, H. A., Lai, Y., Goosen, T. C., Jones, H. M., El-Kattan, A. F., Gosset, J. R., Lin, J., & Varma, M. V. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.759210 · Cited by 68
A Unified Proteochemometric Model for Prediction of Inhibition of Cytochrome P450 Isoforms
Lapins, M., Worachartcheewan, A., Spjuth, O., Georgiev, V., Prachayasittikul, V., Nantasenamat, C., & Wikberg, J. E. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066566 · Cited by 46
Metadata
- Authors
- Obach, R. S., Walsky, R. L., Venkatakrishnan, K., Gaman, E. A., Houston, J. B., & Tremaine, L. M.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2006-01
- Volume
- 316
- Issue
- 1
- Pages
- 336-348
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2096483010
- Cited by
- 433
- References
- 114
- FWCI
- 18.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.